Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Xilio Therapeutics stock price, quote, forecast and news

XLO
US98422T1007

Price

0.89
Today +/-
+0
Today %
+0 %
P

Xilio Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xilio Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xilio Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xilio Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xilio Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xilio Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xilio Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xilio Therapeutics’s growth potential.

Xilio Therapeutics Revenue, EBIT and net profit per share

DateXilio Therapeutics RevenueXilio Therapeutics EBITXilio Therapeutics Net Income
2029e164.98 M undefined0 undefined13.61 M undefined
2028e33.4 M undefined-157.76 M undefined-17.89 M undefined
2027e336,663.3 undefined-152.53 M undefined-44.73 M undefined
2026e6.31 M undefined-79.32 M undefined-37.09 M undefined
2025e37.88 M undefined-36.82 M undefined-35.04 M undefined
2024e15.15 M undefined-53.88 M undefined-52 M undefined
20230 undefined-79.13 M undefined-76.4 M undefined
20220 undefined-89.15 M undefined-88.22 M undefined
20210 undefined-75.04 M undefined-75.8 M undefined
20200 undefined-54.56 M undefined-55.22 M undefined
20190 undefined-19.03 M undefined-17.31 M undefined

Xilio Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201920202021202220232024e2025e2026e2027e2028e2029e
0000015376033164
------146.67-83.78--396.97
-----------
00000000000
-19-54-75-89-79-53-36-79-152-1570
------353.33-97.30-1,316.67--475.76-
-17-55-75-88-76-52-35-37-44-1713
-223.5336.3617.33-13.64-31.58-32.695.7118.92-61.36-176.47
26.6726.6726.6727.3927.5000000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Xilio Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Xilio Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Xilio Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Xilio Therapeutics's financial health and stability.

Assets

Xilio Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Xilio Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Xilio Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Xilio Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2019202020212022
-17-55-75-88
01,0001,0001,000
0000
016-112
-1158
0000
0000
-17-36-80-75
0-2-1-1
0-2-1-1
0000
0000
9000
50102610
60102600
----
0000
41-28178-77
-18.56-38.28-81.85-77.59
0000

Xilio Therapeutics stock margins

The Xilio Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xilio Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xilio Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xilio Therapeutics's sales revenue. A higher gross margin percentage indicates that the Xilio Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xilio Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xilio Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xilio Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xilio Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xilio Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xilio Therapeutics Margin History

Xilio Therapeutics Gross marginXilio Therapeutics Profit marginXilio Therapeutics EBIT marginXilio Therapeutics Profit margin
2029e0 %0 %8.25 %
2028e0 %-472.38 %-53.58 %
2027e0 %-45,306.45 %-13,287.73 %
2026e0 %-1,256.43 %-587.56 %
2025e0 %-97.23 %-92.52 %
2024e0 %-355.63 %-343.26 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %

Xilio Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Xilio Therapeutics earnings per share therefore indicates how much revenue Xilio Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xilio Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xilio Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xilio Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xilio Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Xilio Therapeutics Revenue, EBIT and net profit per share

DateXilio Therapeutics Sales per ShareXilio Therapeutics EBIT per shareXilio Therapeutics Earnings per Share
2029e4.47 undefined0 undefined0.37 undefined
2028e0.9 undefined0 undefined-0.48 undefined
2027e0.01 undefined0 undefined-1.21 undefined
2026e0.17 undefined0 undefined-1 undefined
2025e1.03 undefined0 undefined-0.95 undefined
2024e0.41 undefined0 undefined-1.41 undefined
20230 undefined-2.88 undefined-2.78 undefined
20220 undefined-3.25 undefined-3.22 undefined
20210 undefined-2.81 undefined-2.84 undefined
20200 undefined-2.05 undefined-2.07 undefined
20190 undefined-0.71 undefined-0.65 undefined

Xilio Therapeutics business model

Xilio Therapeutics is one of the most popular companies on Eulerpool.com.

Xilio Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Xilio Therapeutics shares outstanding

The number of shares was Xilio Therapeutics in 2023 — This indicates how many shares 27.496 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xilio Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xilio Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xilio Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xilio Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Xilio Therapeutics.

Xilio Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.11 -0.62  (-458.06 %)2024 Q1
12/31/2023-0.65 -0.64  (0.99 %)2023 Q4
9/30/2023-0.82 -0.61  (25.21 %)2023 Q3
6/30/2023-0.88 -0.7  (20.11 %)2023 Q2
3/31/2023-0.89 -0.83  (7.22 %)2023 Q1
12/31/2022-0.79 -0.82  (-3.42 %)2022 Q4
9/30/2022-0.89 -0.72  (18.76 %)2022 Q3
6/30/2022-0.79 -0.9  (-14.1 %)2022 Q2
3/31/2022-0.94 -0.78  (16.8 %)2022 Q1
12/31/2021-1.18 -0.98  (16.8 %)2021 Q4
1
2

Xilio Therapeutics list of shareholders

%
Name
Stocks
Change
Date
8.14 % Rock Springs Capital Management LP3,003,2591,562,5004/5/2024
7.60 % Bain Capital Life Sciences Investors, LLC2,805,413012/31/2023
7.48 % Atlas Venture2,759,344012/31/2023
5.17 % Fidelity Management & Research Company LLC1,907,671012/31/2023
4.37 % SV Health Investors, LLC1,613,63203/31/2023
4.02 % MRL Ventures Fund, L.L.C.1,483,4141,483,4143/30/2023
4.00 % Takeda Pharmaceutical Co Ltd1,475,12103/31/2023
3.91 % RiverVest Venture Partners, LLC1,441,444012/31/2023
21.22 % Gilead Sciences Inc7,830,723485,2504/2/2024
2.45 % The Vanguard Group, Inc.902,53112,17812/31/2023
1
2
3
4
5
...
7

Xilio Therapeutics Executives and Management Board

Dr. Rene Russo48
Xilio Therapeutics President, Chief Executive Officer, Director
Compensation 2.21 M
Dr. Martin Huber63
Xilio Therapeutics President and Head of R & D, Chief Medical Officer
Compensation 1.35 M
Mr. Paul Clancy61
Xilio Therapeutics Independent Chairman of the Board
Compensation 88,687
Mr. Tomas Heyman67
Xilio Therapeutics Independent Director
Compensation 76,742
Ms. Sara Bonstein42
Xilio Therapeutics Independent Director
Compensation 68,288
1
2
3

Most common questions regarding Xilio Therapeutics

What is the P/E ratio of Xilio Therapeutics 2024?

The Xilio Therapeutics P/E ratio is -0.47.

What is the P/S ratio of Xilio Therapeutics 2024?

The Xilio Therapeutics P/S ratio is 1.62.

What is the AlleAktien quality score of Xilio Therapeutics?

The AlleAktien quality score for Xilio Therapeutics is 2/10.

What is the revenue of Xilio Therapeutics 2024?

The expected Xilio Therapeutics revenue is 15.15 M USD.

How high is the profit of Xilio Therapeutics 2024?

The expected Xilio Therapeutics profit is -52 M USD.

What is the business model of Xilio Therapeutics

No history available for Xilio Therapeutics.

What is the Xilio Therapeutics dividend?

Xilio Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Xilio Therapeutics pay dividends?

The dividend cannot currently be calculated for Xilio Therapeutics or the company does not pay out a dividend.

What is the Xilio Therapeutics ISIN?

The ISIN of Xilio Therapeutics is US98422T1007.

What is the Xilio Therapeutics ticker?

The ticker of Xilio Therapeutics is XLO.

How much dividend does Xilio Therapeutics pay?

Over the past 12 months, Xilio Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xilio Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Xilio Therapeutics?

The current dividend yield of Xilio Therapeutics is .

When does Xilio Therapeutics pay dividends?

Xilio Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xilio Therapeutics?

Xilio Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Xilio Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xilio Therapeutics located?

Xilio Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xilio Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xilio Therapeutics from 8/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/3/2024.

When did Xilio Therapeutics pay the last dividend?

The last dividend was paid out on 8/3/2024.

What was the dividend of Xilio Therapeutics in the year 2023?

In the year 2023, Xilio Therapeutics distributed 0 USD as dividends.

In which currency does Xilio Therapeutics pay out the dividend?

The dividends of Xilio Therapeutics are distributed in USD.

All fundamentals about Xilio Therapeutics

Our stock analysis for Xilio Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xilio Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.